To confirm a diagnosis and determine the stage of the disease, your doctor will use a series of tests: Biopsy: This is the most definitive test. A surgeon will remove all or part of an affected lymph ...

Every year, more than 80,000 Americans hear these life-changing words: You have non-Hodgkin’s lymphoma, a blood cancer.

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma PURPOSE: Classical Hodgkin's disease and non-Hodgkin's B-cell lymphoma ...

Patients with early-stage classic Hodgkin lymphoma and other neoplasms exhibited higher risk for cardiovascular disease-associated mortality compared with cancer-associated mortality later in life, ...

Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse PURPOSE: The cumulative incidence for non-Hodgkin lymphoma’s ...

Hodgkin’s lymphoma is rapidly expanding, driven by innovative clinical advancements and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, ...

EMBL researchers and collaborators have developed SDR-seq, a breakthrough single-cell technology that captures DNA and RNA ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

The global Cutaneous T-cell Lymphoma (CTCL) market is witnessing significant growth due to increasing disease prevalence, particularly among older populations, and advancements in diagnostic ...